Sunday, June 06, 2021

Immunotherapy after bladder cancer surgery may reduce recurrence, study shows


News Release 3-Jun-2021
New research found that using nivolumab reduced bladder cancer recurrence after surgery compared to patients who received placebo
Memorial Sloan Kettering Cancer Center


New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in the New England Journal of Medicine.


No comments:

Post a Comment